Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8236 to 8250 of 8962 results

  1. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

    Technology appraisal guidance
    Discontinued

  2. Venous thromboembolism - apixaban (acute medical illness) [ID310]

    Discontinued Reference number: GID-TAG419

    Technology appraisal guidance
    Discontinued

  3. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  4. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

    Technology appraisal guidance
    Discontinued

  5. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  6. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued Reference number: GID-TAG454

    Technology appraisal guidance
    Discontinued

  7. Venous thromboembolism (recurrent) - idraparinux sodium [ID395]

    Discontinued Reference number: GID-TAG384

    Technology appraisal guidance
    Discontinued

  8. Osteoarthritis - diacerein [ID332]

    Discontinued Reference number: GID-TAG250

    Technology appraisal guidance
    Discontinued

  9. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

    Technology appraisal guidance
    Discontinued

  10. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  11. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  12. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued Reference number: GID-TA11240

    Technology appraisal guidance
    Discontinued

  13. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued Reference number: GID-TA11239

    Technology appraisal guidance
    Discontinued

  14. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued Reference number: GID-TA11238

    Technology appraisal guidance
    Discontinued

  15. Mastocytosis (systemic) - masitinib [ID781]

    Discontinued Reference number: GID-TA10019

    Technology appraisal guidance
    Discontinued